D.E. Shaw & Co
SBBP

D.E. Shaw & Co’s Strongbridge Biopharma plc. SBBP Stock Holding History

D.E. Shaw & Co’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-80,912
Closed -$306K – 4310
2020
Q2 		$306K Sell
80,912
-153,382
-65% -$460K ﹤0.01% 3618
2020
Q1 		$443K Sell
234,294
-337,931
-59% -$878K ﹤0.01% 3269
2019
Q4 		$1.2M Sell
572,225
-327,008
-36% -$627K ﹤0.01% 2856
2019
Q3 		$2.15M Sell
899,233
-50,848
-5% -$137K ﹤0.01% 2286
2019
Q2 		$2.97M Buy
950,081
+192,760
+25% +$708K ﹤0.01% 1972
2019
Q1 		$3.77M Buy
757,321
+401,447
+113% +$1.98M ﹤0.01% 1737
2018
Q4 		$1.59M Buy
355,874
+168,243
+90% +$821K ﹤0.01% 2340
2018
Q3 		$910K Buy
187,631
+115,200
+159% +$589K ﹤0.01% 2750
2018
Q2 		$435K Buy
+72,431
New +$530K ﹤0.01% 3193

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co's SBBP Position: Q3 2020 in Review

D.E. Shaw & Co sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2020, closing a stake of 80,912 shares — an estimated $306K sold.

D.E. Shaw & Co first reported a position in SBBP in Q2 2018 and held it in 9 quarters. The position peaked at $3.77M in Q1 2019. 77 funds tracked by Wall St. Rank hold SBBP as of Q3 2020.

  • D.E. Shaw & Co reported no remaining Strongbridge Biopharma plc. position as of Q3 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 80,912 Strongbridge Biopharma plc. shares in Q3 2020, an estimated $306K.
  • D.E. Shaw & Co first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 9 quarters.
  • D.E. Shaw & Co's Strongbridge Biopharma plc. position peaked at $3.77M in Q1 2019.
  • 77 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2020.

Based on D.E. Shaw & Co's 13F filing for Q3 2020, filed 16 Nov 2020.